Thanks for joining DividendStocks.com, the daily newsletter built for dividend and income investors like you. We’re thrilled to have you on board and can’t wait to help you discover the best dividend opportunities out there. Before we can start sending your daily insights, please take a quick moment to confirm your subscription: Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Why wait? Let’s get your dividend journey started! Click Here to Start Discovering Top Income-Generating Stocks See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Special Report Why Wall Street Gave Up on Pfizer—and Why That May Be a MistakeBy Jeffrey Neal Johnson. Originally Published: 12/31/2025. 
What You Need to Know - Pfizer trades at a historic discount compared to its peers while paying a dividend yield that significantly outperforms the broader market average.
- Strategic acquisitions have established a robust pipeline of next-generation cancer treatments, which are driving growth.
- Management has aggressively re-entered the weight-loss market with new assets, including one that offers a convenient monthly dosing schedule for patients.
The market of 2025 will be remembered for its extremes. While investors poured billions into technology sector giants and companies manufacturing weight-loss drugs, traditional pharmaceutical leaders were left in the cold. Nowhere is this more evident than with Pfizer Inc. (NYSE: PFE). Trading near multi-year lows around $25, the company finished the year as one of the most unloved assets in the S&P 500. To the casual observer, the pessimism seems justified: the company has spent the last two years battling a perfect storm. Revenue from COVID-19 products vanished faster than anticipated, high-profile pipeline candidates failed in trials, and activist investors launched a public campaign against management. A new trading briefing is drawing attention to a little-discussed policy-driven market theme some traders believe could create short-term opportunities.
In a recent video, a veteran technical analyst walks through how this setup works, why it's showing unusual momentum, and how active traders are approaching it using defined, time-bound strategies rather than long-term buy-and-hold positions. Watch the trading briefing here But smart investing often requires venturing where others refuse to go. With the exit of activist investor Starboard Value in November and a realistic reset of guidance, the storm appears to have passed. The bad news is largely priced in, and Pfizer's stock price has likely found a floor. As we enter 2026, Pfizer presents a rare scenario: a blue-chip company trading at a distressed price, offering a solid dividend yield while it quietly rebuilds its future. The Mathematical Case: Why the Price Is Wrong For value investors, the case for Pfizer comes down to simple arithmetic. The market is pricing the company as if its earnings will permanently shrink, creating a stark disconnect between share price and the company's underlying cash generation. A Historic Valuation Gap Pfizer currently trades at a forward price-to-earnings ratio (P/E) of roughly 8.6x. By comparison, the average company in the pharmaceutical sector trades at 15x to 20x earnings, and high-growth peers such as Eli Lilly (NYSE: LLY) carry even higher multiples. At ~8.6x earnings, the market is effectively assigning near-zero growth expectations. That sets a low bar: Pfizer doesn't need a miracle to see upside. It simply needs to demonstrate stability or modest growth. Any positive earnings surprise could trigger multiple expansion as the stock re-rates toward industry averages. The Dividend Shield While the market waits for repricing, investors are being paid to hold the stock. - Annual Payout: $1.72 per share.
- Current Yield: Approximately 6.9%.
That yield is roughly four times the S&P 500 average and serves as a margin of safety. Even if the share price remains flat through 2026, a near-7% dividend provides a strong baseline return that outpaces most savings accounts and government bonds. Management is working to protect the dividend via a $4 billion cost-saving program. By cutting administrative bloat and optimizing manufacturing, they are prioritizing the cash flow needed to keep those quarterly payments intact. The New Foundation: Oncology Takes the Lead A common critique of Pfizer is that the decline of its COVID business left a growth gap. To fill it, the company has pivoted aggressively toward oncology. The "Guided Missile" Technology The centerpiece of Pfizer's 2023 acquisition of Seagen is leadership in antibody-drug conjugates (ADCs). Traditional chemotherapy is like a wide blast that harms both healthy and cancerous cells. ADCs act more like guided missiles: they target specific cancer cells and deliver a toxic payload directly, sparing healthy tissue. This technology is already producing revenue. The Seagen portfolio contributed about $3.4 billion in 2024 and generated $2.75 billion in the first three quarters of 2024, driven by strong sales of Padcev for bladder cancer. Navigating the Bumps The path hasn't been entirely smooth. In December 2025, Pfizer reported a safety signal associated with a candidate called Hympavzi, including a patient death in a trial extension. While this caused a temporary market reaction, it doesn't derail the broader thesis. The oncology portfolio is large—more than 60 programs in development—and management has continued to reinforce the pipeline, for example by licensing a promising bispecific antibody from 3SBio. Catching Up: The Strategy for Weight Loss After an early setback in the GLP-1 oral space with Danuglipron, Pfizer didn't abandon the obesity opportunity. In late 2025 the company executed a two-pronged approach to re-enter the market. The Injectable Strategy (Metsera) In November, Pfizer acquired Metsera for roughly $7 billion, gaining an injectable candidate (MET-097i) that could be administered monthly rather than weekly—an important convenience advantage if efficacy matches expectations. The Oral Strategy (YaoPharma) Pfizer also signed a licensing deal with YaoPharma for a small-molecule GLP-1 candidate, addressing patients who prefer oral medications. Why This Matters Today's stock price reflects little to no value for Pfizer's obesity pipeline. With expectations so low, any clinical progress from Metsera or YaoPharma assets would represent pure upside. Pfizer doesn't need to win the race outright; it only needs to capture a meaningful slice of what could become a $100 billion market. The Risk/Reward Equation: 2026 Belongs to Value Pfizer enters 2026 as a company in transition but with a fortified balance sheet. Management has set a revenue floor of roughly $61 billion for 2026—a realistic target that removes some of the uncertainty that weighed on the stock. For investors, the math is straightforward. At about $25 per share, downside is cushioned by a healthy dividend and a valuation at historic lows. The upside is significant: continued oncology growth or meaningful progress in weight-loss candidates could trigger a sharp re-rating. Unloved stocks one year often become standouts the next. With activist pressure behind it and the balance sheet stabilized, Pfizer has shifted from a "falling knife" into a potential core holding for value-oriented portfolios. 2026 could be the year the sleeping giant wakes up.
| 
